2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens
2006
Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study
Whitehead R, McCoy S, Wollner I, Wong L, Harker W, Hoff P, Gold P, Billingsley K, Blanke C. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. Journal Of Clinical Oncology 2006, 24: 3598-3598. DOI: 10.1200/jco.2006.24.18_suppl.3598.Peer-Reviewed Original ResearchPrior chemotherapy regimensAdvanced colorectal cancerPhase II trialColorectal cancerEligible patientsChemotherapy regimensII trialPerformance statusSouthwest Oncology Group studyCommon grade 2Prior chemotherapy regimenZubrod performance statusMetastatic colorectal cancerMonths overall survivalColorectal cancer patientsSerum magnesium levelsSignificant anti-tumor activityKaplan-Meier estimatesAdditional active agentsAnti-tumor activityHistone deacetylase inhibitorsMurine model systemBaseline labsMeasurable diseasePrior regimens